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Introduction
Development and life-long maintenance of the bones compris-
ing the mammalian skeleton is evolutionarily conserved and 
tightly regulated (Karsenty et al., 2009). The modeling of skeletal 
elements during development, largely starting from cartilaginous 
templates, requires the coordinated actions of matrix-resorbing 
osteoclasts and matrix-producing osteoblasts. The mature skel-
eton is then constantly remodeled by the coupled activities   
of these two cell types. With age, bone formation decreases   
below the level required to compensate for the often-increased 
bone resorption, leading to osteoporosis with its associated 
fractures. It is therefore of great clinical importance to iden-
tify and characterize in depth the molecular mechanisms that 
regulate osteoblast differentiation, osteoblast function, and, hence, 
bone formation.
Osteoblasts differentiate from mesenchymal precursor cells, 
which can also give rise to adipocytes, chondrocytes, and myo-
blasts (Harada and Rodan, 2003). Downstream of key osteogenic 
signaling pathways, such as bone morphogenetic protein/Smad 
or canonical Wnt, lineage-specific transcription factors regulate 
specific steps in the progressive transition from early mesen-
chymal cells to the fully differentiated bone matrix–producing 
osteoblasts (Karsenty et al., 2009).
Runx2, a Runt domain transcription factor, is essential for 
the commitment of early mesenchymal cells to the osteoblast 
lineage (Ducy et al., 1997; Karsenty et al., 2009). In addition, 
Runx2 controls the differentiation and function of the osteo-
blast in concert with other factors such as Osterix (Osx) by 
regulating the expression of many osteoblast-related genes 
R
unx2 is indispensable for osteoblast lineage com-
mitment and early differentiation but also blocks 
osteoblast maturation, thereby causing bone loss 
in Runx2 transgenic mice. Zinc finger protein 521 (Zfp521) 
antagonizes Runx2 in vivo. Eliminating one Zfp521 allele 
mitigates the cleidocranial dysplasia–like phenotype of 
newborn Runx2
+/ mice, whereas overexpressing Zfp521 
exacerbates  it.  Overexpressing  Zfp521  also  reverses   
the severe osteopenia of adult Runx2 transgenic mice. 
Zfp521 binds to both Runx2 and histone deacetylase 3 
(HDAC3), promotes their association, and antagonizes 
Runx2 transcriptional activity in an HDAC3-dependent 
manner. Mutating the Zfp521 zinc finger domains 6 and 
26 reduces the binding of Zfp521 to Runx2 and inhibi-
tion of Runx2 activity. These data provide evidence that 
Zfp521 antagonizes Runx2 in vivo and thereby regu-
lates two stages of osteoblast development, early during 
mesenchymal cell lineage commitment and later during 
osteoblast maturation. Thus, the balance and molecular 
interplay between Zfp521 and Runx2 contribute to the 
control of osteoblast differentiation, skeletal develop-
ment, and bone homeostasis.
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Results
Zfp521 modulates the CCD phenotype in  
Runx2
+/ mice
Runx2
+/ mice display features of the human heritable disease 
CCD, including hypoplastic clavicles, a hypoplastic hyoid bone 
with a delay in mineralization, and open fontanelles (Mundlos   
et al., 1997; Otto et al., 1997). Because this phenotype is a con-
sequence of the reduced Runx2 gene dose, we hypothesized that 
if Zfp521 indeed antagonizes Runx2 in vivo, removing one al-
lele of Zfp521 would lessen the CCD phenotype, whereas over-
expressing Zfp521 would enhance it. To test this hypothesis 
under physiological conditions, we used the compound hetero-
zygous strategy. First we generated mice with a heterozygous 
germline deletion of Zfp521 (Zfp521
+/) and crossed these ani-
mals with Runx2
+/ mice to generate Zfp521
+/;Runx2
+/ double 
heterozygous mice, Zfp521
+/ and Runx2
+/ single heterozygous 
mice, and wild-type (Wt) littermates. Analysis of postnatal day 
(P) 0 skeletal preparations revealed that the length of both the 
clavicle and the mineralized midportion of the hyoid bone was 
significantly increased in Zfp521
+/ mice compared with Wt lit-
termates. Furthermore, the hypoplasia of the clavicle and the 
delayed mineralization of the midportion of the hyoid bone   
of the Runx2
+/ mice were partially normalized in the Zfp521
+/; 
Runx2
+/ mice (Fig. 1, A and B), suggesting that Zfp521 indeed 
acts to oppose Runx2-induced osteoblast differentiation and 
bone mineralization under physiological conditions in vivo.
We sought to further investigate the Zfp521-mediated an-
tagonism of Runx2 activity by generating bitransgenic mice in 
which overexpression of Zfp521 was regulated by the enolase 2 
(ENO2) promoter (ENO2-tTA;TetOp-Zfp521 mice, hereafter re-
ferred to as Zfp521
Tg mice). We successfully used this bitrans-
genic system in earlier osteoblast-related work (Sabatakos et al., 
2000, 2008; Rowe et al., 2009) and selected it for this study be-
cause the ENO2 promoter is active in both early osteoblasts 
(Fig. S1 A) and in more mature osteoblasts in the long bones of 
adult mice (Fig. S4 A). In addition, the ENO2 promoter is not 
regulated by Runx2 (unpublished data), unlike many of the 
classical promoters used to control overexpression in subsets of 
osteoblasts such as Osx, Collagen I, or Osteocalcin.
In brief, Zfp521
Tg mice were crossed with Runx2
+/ mice 
to generate Zfp521
Tg;Runx2
+/ compound mice, Zfp521
Tg mice, 
Runx2
+/ mice, and Wt littermates. Analysis of skeletal prepara-
tions revealed that at P2, the clavicle and hyoid bone of the   
Zfp521
Tg mice were hypoplastic and intermediate between Wt and 
Runx2
+/ mice (Fig. 1, C and D). More importantly, the CCD 
phenotype of the Runx2
+/ mice was significantly enhanced in 
the Zfp521
Tg;Runx2
+/ compound mice, in which the rudimen-
tary clavicle was greatly reduced in length and thickness (Fig. 1 C), 
and the midportion of the hypoplastic hyoid bone lacked any 
mineralization at P2 (Fig. 1 D). The Runx2
+/ mice demon-
strated a clearly defined nonmineralized area between the ante-
rior and posterior fontanelles at 25 d of age, which was strikingly 
larger in the Zfp521
Tg;Runx2
+/ mice (Fig. 1 E). These data dem-
onstrate that Zfp521 antagonizes the pro-osteogenic function of 
Runx2 at early stages of osteoblast commitment and differentia-
tion in vivo.
(e.g., collagen I, osteocalcin, MMP13, and osteopontin; Nakashima 
et al., 2002; Stein et al., 2004), including the Runx2 gene itself 
(Drissi et al., 2000).
Knockout (Ko) studies have demonstrated that the skele-
tons of Runx2
/ mice are blocked at the cartilage stage without 
mineralized bones because of a lack of osteoblast differentia-
tion, illustrating the requirement of Runx2 at early stages of   
osteoblast differentiation. Because of the failure of the skeleton 
to mineralize, Runx2
/ animals suffer from respiratory insuffi-
ciency and die shortly after birth (Komori et al., 1997; Otto 
et al., 1997). The biological and clinical relevance of Runx2 
was further demonstrated by the identification of mutations in   
the Runx2 gene locus in humans with autosomal dominant   
cleidocranial dysplasia (CCD; Mundlos et al., 1997). Because of 
the reduced Runx2 gene dose caused by these mutations, affected 
patients develop clavicle hypoplasia and craniofacial abnormal-
ities, a phenotype that is largely recapitulated in mice hetero-
zygous for Runx2 (Mundlos et al., 1997; Otto et al., 1997, 2002).
In sharp contrast to the positive effect of Runx2 on osteo-
blast lineage commitment and early osteoblast differentiation, 
it has been hypothesized that Runx2 may inhibit osteoblast 
maturation because overexpression of Runx2 targeted to differ-
entiating osteoblasts leads to osteopenia and ultimately spo-
radic fractures of the hind-limb long bones in adult mice (Liu 
et al., 2001; Geoffroy et al., 2002). These findings suggest that 
the effect of Runx2 activity on osteoblast function and bone 
mass may be differentiation stage dependent. Thus, as much as 
Runx2 is necessary for the commitment and early differentia-
tion of osteoblast precursors, the attenuation of its activity at 
later stages is likely equally important for the final maturation 
and function of osteoblasts (Lian and Stein, 2003). Negative 
regulation of Runx2 activity can occur at the transcriptional 
and posttranslational level and is exerted by a complex inter-
play of a variety of factors, including transcriptional repressors 
(de Frutos et al., 2009), homeodomain proteins (Hassan et al., 
2004, 2009), and histone deacetylases (HDAC; Westendorf   
et al., 2002; Schroeder et al., 2004; Kang et al., 2005; Jensen   
et al., 2008, 2009).
We recently reported zinc finger protein 521 (Zfp521) as a 
transcriptional repressor that attenuates Runx2 activity in vitro 
(Wu et al., 2009). In the present study, we establish the repres-
sive role of Zfp521 on Runx2 and early osteoblast differentia-
tion in vivo by genetic experiments, demonstrating that removing 
one allele of Zfp521 partially rescues the CCD phenotype of 
Runx2
+/ mice, whereas overexpressing Zfp521 enhances it. We 
then identify the molecular mechanism underlying the repres-
sion of Runx2 transcriptional activity by Zfp521 and demon-
strate that Zfp521 also interacts with the corepressor HDAC3, 
stabilizing the interaction between Runx2 and HDAC3. Finally, 
we test the hypothesis that Runx2 indeed exerts opposite functions 
at early and late stages of osteoblast differentiation and find that 
overexpressed Zfp521 prevents the onset of osteopenia and spo-
radic long bone fractures in Runx2 transgenic mice. Together, 
these findings provide strong in vivo evidence for both the phys-
iological repression of Runx2 by Zfp521 and the dual role of 
Runx2, favoring osteoblast commitment and early differentia-
tion but opposing osteoblast maturation.1273 Zfp521 controls bone mass • Hesse et al.
overexpressing Zfp521 (Fig. 2 B). To confirm the repression of 
Runx2 expression by Zfp521, we analyzed the level of Runx2   
protein in osteoblasts from the Zfp521
Tg mice. Indeed, both   
immunofluorescence microscopy and immunoblot analysis 
showed that Runx2 protein was reduced in the osteoblasts de-
rived from Zfp521
Tg mice (Fig. 2 C).
To further examine the effect of Zfp521 on Runx2 tran-
scriptional activity, we used a luciferase reporter gene driven by 
six concatenated osteoblast-specific element 2 (OSE2) cassettes 
(6×OSE2-luc; Ducy and Karsenty, 1995). Zfp521 alone had no 
effect on the reporter activity but completely blocked the Runx2-
mediated promoter activation in a dose-dependent manner, and 
Runx2 dose-dependently reversed the Zfp521-induced inhibi-
tion (Fig. S1 B).
Consistent with the delayed mineralization in vivo, pri-
mary calvarial osteoblasts from Zfp521
Tg mice displayed re-
duced alkaline phosphatase (ALP) activity (Fig. 2 D). Similarly, 
Zfp521 repressed ALP activity in osteoblasts (Fig. S1 C) and in 
MC3T3-E1 cells stably overexpressing Zfp521 (not depicted). 
This repression was dose-dependently rescued by coinfection 
with Runx2 adenovirus (Fig. S1 C). Collectively, these results 
indicate that Zfp521 attenuates Runx2 activity and restricts early 
osteoblast differentiation.
Runx2  also  antagonizes  the  proliferation  of  osteoblast 
precursors (Galindo et al., 2005), which may contribute to the 
osteoblast phenotype. To determine whether Zfp521 modulates 
the  proliferation  of  osteoblast  precursor  cells,  we  quantified 
[
3H]thymidine incorporation by calvarial cells obtained from 
Zfp521
Tg mice and control littermates. Zfp521 had no detectable 
effect on the thymidine incorporation (Fig. 2 E), suggesting that 
the reduced osteoblast phenotype seen in our assays was pri-
marily caused by an impaired commitment to the osteoblast   
lineage and/or to a reduced osteoblast differentiation and not a 
proliferation-related effect of Zfp521.
Next, we hypothesized that the block in the differentiation 
of early stage osteoblasts derived from Zfp521
Tg mice might 
lead to an increase in the abundance of mesenchymal precursor 
cells, which would then accumulate. To test this hypothesis, we 
analyzed the precursor capability of bone marrow stromal cells 
derived from adult Zfp521
Tg mice and control littermates using 
standardized fibroblastic (colony-forming unit–fibroblast [CFU-F]) 
and mineralizing (colony-forming unit–osteoblast [CFU-OB]) 
colony-forming unit assays and found that both CFU-F and 
CFU-OB were indeed increased in Zfp521-overexpressing mice 
(Fig. 2 F). In summary, these data demonstrate that Zfp521 re-
duces Runx2 activity and expression and restricts early stage 
osteoblast differentiation but not proliferation, resulting in an 
accumulation of mesenchymal precursor cells.
Zfp521 zinc finger (ZF) domains 6 and 26 
mediate the interaction with Runx2 and the 
inhibition of Runx2 transcriptional activity
At the molecular level, coimmunoprecipitation assays showed 
that Zfp521 associates with Runx2 in osteoblasts not only in an 
overexpression system (Fig. S2 A; Wu et al., 2009) but also, and 
more importantly, under endogenous conditions (Fig. 3 A). To   
identify the Runx2 domains that are required for the interaction 
Zfp521 antagonizes Runx2 transcriptional 
activity and early stage osteoblast 
differentiation, leading to an accumulation 
of mesenchymal precursor cells
Based on our in vivo observations, we proceeded to analyze the 
effects of Zfp521 on Runx2 at the cellular and molecular levels. 
At the cellular level, we determined the expression of Runx2 
and its direct target gene Osx (Nakashima et al., 2002) in early 
stage osteoblasts derived from neonatal Zfp521
+/ and Zfp521
Tg 
mice. Consistent with the in vivo findings, Zfp521
+/ osteoblasts 
demonstrated a higher expression of Runx2 and Osx compared 
with control (Fig. 2 A), whereas the expression of both Runx2 
and Osx was significantly reduced in osteoblasts constitutively 
Figure  1.  Zfp521  is  a  physiological  antagonist  of  Runx2  in  vivo.   
(A) At postnatal day 0 (P0), Zfp521
+/ mice present a modestly elongated 
clavicle compared with Wt mice. Runx2
+/ mice exhibit a very severe 
hypoplasia of the clavicle, which is mitigated in Runx2
+/;Zfp521
+/ mice 
(arrows). (B) Compared with Wt mice, Zfp521
+/ mice demonstrate a more 
strongly mineralized midportion of the hyoid bone. The delayed mineral-
ization of the midportion of the hyoid bone in Runx2
+/ mice is rescued in 
Runx2
+/;Zfp521
+/ mice (arrows). (C) A progressively severe hypoplasia 
of the clavicle was seen in postnatal day 2 (P2) Zfp521
Tg mice, Runx2
+/ 
mice, and Zfp521
Tg;Runx2
+/ mice (arrows). (D) The midportion of the 
hyoid bones of P2 Zfp521
Tg mice, Runx2
+/ mice, and Zfp521
Tg;Runx2
+/ 
mice show a progressive decrease in size and mineralization (arrows).   
(E) The calvaria of postnatal day 25 (P25) Zfp521
Tg mice were similar to the 
calvaria of Wt mice. Runx2
+/ mice exhibited open anterior and posterior 
fontanelles and wide cranial sutures, which were strikingly enhanced in 
Zfp521
Tg;Runx2
+/ mice (arrows). Skeletal structures were measured. Data 
are mean ± SEM. *, P < 0.05 versus Wt. 
#, P < 0.05 versus Runx2
+/. 
Littermates were analyzed as controls. Results are representative of six to 
eight animals. Bars, 1 mm.JCB • VOLUME 191 • NUMBER 7 • 2010   1274
interact (Fig. 3 E). Similarly, only the ZF 26–30 fragments with 
an intact ZF 26 associated with Runx2 (Fig. 3 F).
To  determine  whether  destabilizing  the  conformations  of 
ZFs 6 and 26 was sufficient to disable the binding of the full-length 
Zfp521 to Runx2, the zinc-coordinating histidine residues of ZF 
domains 6 and 26 (H
264, H
269, H
1156, and H
1161) were mutated to 
glutamic  acid.  Coimmunoprecipitation  of  Wt  Runx2  and  full-
length Zfp521 bearing disabled ZF domains 6 and 26 revealed a 
greatly reduced association of the two molecules (Fig. S2 B).
We then examined how disabling the zinc coordination of 
the ZF 6 and ZF 26 domains affected Zfp521’s ability to antago-
nize Runx2-dependent transactivation of the 6×OSE2-luc re-
porter assay. As before, Wt Zfp521 completely abolished the 
Runx2-mediated promoter activation. In contrast to the com-
plete inhibition by the Wt protein, the mutated Zfp521 reduced 
the Runx2-induced reporter activity by 50% (Fig. 3 G), indi-
cating the functional importance of these two domains. Similar 
results were obtained using the Osteocalcin promoter-driven   
luciferase (OG2-luc) reporter (unpublished data).
Zfp521 antagonizes Runx2 activity in an 
HDAC3-dependent manner
In  identifying  the  mechanism  by  which  Zfp521  antagonizes 
Runx2 activity, we first examined its effect on the binding of 
Runx2 to DNA. Coexpressing Zfp521 had no effect on the abil-
ity of Runx2 to bind to oligonucleotides that contained either 
the  rat  Osteocalcin  promoter  OG2  response  element  or  the 
mouse Osteocalcin promoter OSE2 response element (Fig. 4 A; 
Ducy and Karsenty, 1995), indicating that Zfp521 does not 
with Zfp521, we expressed a series of progressively truncated 
Runx2 fragments that together encompass the entire Runx2 
molecule in HEK-293 cells and determined which fragments 
bound to a GST-Zfp521 fusion protein (Fig. 3 B). Immunoblot 
analysis revealed that Zfp521 interacted with Runx2 fragments 
that contained the Runt and the QA domain but not with the   
isolated repressor domain.
We then investigated the features of Zfp521 that mediate 
the Runx2–Zfp521 interaction. Because ZF-mediated inter-
actions often depend on the zinc ion–stabilized conformation of 
the ZF domain (Turner and Crossley, 1999), we first tested how 
chelating the zinc ions affected the Zfp521–Runx2 interaction. 
Removing the zinc ions significantly reduced the interaction of 
Zfp521 with Runx2 (Fig. 3 C).
To identify the ZF domains that interact with Runx2, we 
analyzed the binding of Runx2 to a series of fragments that 
spanned the entire length of Zfp521 (Fig. 3 D). Runx2 bound 
strongly to the fragments that comprised ZFs 6–10 and ZFs 
26–30 and, to a lesser degree, with the ZF 21–25 fragment, 
suggesting that Zfp521 contains at least two Runx2-interacting 
sites, one located near the N terminus and the other near the   
C terminus.
We next generated a library of constructs in which the ZF 
histidines of the ZF 6–10 and ZF 26–30 fragments were ran-
domly mutated to glutamic acid, abolishing the zinc ion coordi-
nation and destabilizing the conformation of the mutated ZFs. 
We found the ZF 6–10 fragments with an intact ZF 6 coimmuno-
precipitated  with  Runx2,  regardless  of  whether  ZFs  7–10 
were mutated, whereas those with a mutation in ZF 6 did not 
Figure 2.  Zfp521 inhibits early stage osteoblast differentia-
tion and increases the number of osteoprogenitors. (A) Gene 
expression analysis revealed that Runx2 and Osx mRNA ex-
pression  was  significantly  increased  in  Zfp521
+/  neonatal 
calvarial osteoblasts compared with Wt mice. (B) Runx2 and 
Osx mRNA expression was significantly decreased in calvarial   
osteoblasts isolated from Zfp521
Tg mice. (C) Immunostaining and 
immunoblot (IB) analysis showed reduced Runx2 expression in 
calvarial osteoblasts from Zfp521
Tg mice and Wt littermates. 
Nuclei were stained with ToPro. Results are representative of 
three independent experiments. Bars, 10 µm. (D) Cultured cal-
varial cells from Zfp521
Tg mice and control littermates were 
stained for ALP activity, or the cells were lysed, and ALP activity 
was determined colorimetrically. ALP activity was reduced in 
cells overexpressing Zfp521. Bars, 5 mm. (E) [
3H]Thymidine 
incorporation  by  calvarial  osteoblasts  from  Zfp521
Tg  mice 
and control littermates showed no changes in osteoblast pro-
liferation. (F) Zfp521
Tg mice contained an increased number 
of colony-forming unit–fibroblast (CFU-F) and colony-forming 
unit–osteoblast (CFU-OB). All results are representative of three 
to eight animals. All data are shown as mean ± SEM. *, P < 
0.05 versus Wt.1275 Zfp521 controls bone mass • Hesse et al.
repression of Runx2-induced 6×OSE2-luc reporter activity by 
Zfp521 but had little effect on Runx2 alone (Fig. 4 B), implicat-
ing HDACs in the Zfp521-induced repression of Runx2.
To determine whether Zfp521 repressed Runx2 activity 
by recruiting the HDAC-containing NuRD complex, we de-
leted the NuRD binding site and confirmed that the truncated 
protein (13Zfp521) failed to interact with components of the 
NuRD complex (Fig. S3 A). The truncated mutant repressed 
the Runx2-induced 6×OSE2-luc reporter gene activity to the 
same extent as Wt Zfp521 (Fig. 4 C), indicating that the NuRD 
complex does not participate in the Zfp521-mediated repres-
sion of Runx2.
Because HDAC5, which is not part of the NuRD complex, 
also antagonizes Runx2 (Kang et al., 2005), we next tested 
the function of Zfp521 in rat osteosarcoma cell line (ROS) 
cells that stably express a dominant-negative form of HDAC5 
repress Runx2 activity by preventing the association of Runx2 
with its consensus DNA binding site, the mechanism used by 
Twist, another Runx2 antagonist that regulates skeletogenesis 
(Bialek et al., 2004).
We then considered the possibility that Zfp521 could re-
cruit  the  repressor  machinery  to  Runx2.  HDACs  antagonize 
Runx2 activity (Westendorf et al., 2002; Schroeder et al., 2004; 
Kang et al., 2005; Jensen et al., 2008, 2009), and a conserved 
motif encoding the first 13 amino acids at the N terminus of early 
hematopoietic ZF protein, the human homologue of Zfp521, 
binds the nucleosome remodeling and HDAC (NuRD) complex, 
which contains HDAC1, HDAC2, MTA2, and RbAp48 (Bond   
et al., 2008). We therefore hypothesized that Zfp521 antagonizes 
Runx2 activity by recruiting HDACs to the transcription com-
plex. Consistent with this hypothesis, the class I and class II 
HDAC inhibitor trichostatin A (TSA) completely blocked the 
Figure  3.  Structure–function  analysis  of  the  Zfp521–Runx2 
interaction. (A) Runx2 was immunoprecipitated (IP) from lysate 
of Wt calvarial osteoblasts, and the immune complexes were 
immunoblotted (IB) for Zfp521 and Runx2. Nonimmune IgG 
was the immunoprecipitated control. Presence of Zfp521 and 
Runx2 in total cell lysate (TCL) is shown. (B) Wild-type (WT) 
Xpress-Runx2 and fragments of Runx2 were overexpressed in 
HEK-293 cells, and the binding to immobilized GST-Zfp521 
was determined by pull-down (PD) followed by immunoblotting 
(top). The expression of Runx2 proteins was confirmed by im-
munoblotting of cell lysates (middle). The schematic drawing 
shows Runx2 domains (AD, QA, Runt, PST, and RD) and the 
truncated forms. The binding of each fragment is indicated.   
(C) Chelating zinc ions with either EDTA or phenanthroline abol-
ished the interaction of Flag-Runx2 with HA-Zfp521. HA-Zfp521 
was immunoprecipitated with anti-HA in HEK-293 cells, and 
the immune complex was immunoblotted for Flag-Runx2 using 
anti-Flag antibody. (D) HA-tagged fragments of Zfp521 con-
taining five zinc fingers (ZFs) each were constructed as shown 
in the schematic drawing. Each fragment was overexpressed 
(second panel, cell lysate) along with Flag-Runx2 (third panel, 
cell lysate) in HEK-293 cells and subjected to coimmunoprecipi-
tation (top). Runx2 bound to the fragments containing ZFs 6–10 
and 26–30 (summarized next to schematic drawing). (E and F) 
Zinc-coordinating His residues in fragments ZF 6–10 (E) and   
ZF 26–30 (F) were randomly mutated to disrupt individual ZF   
conformation. HA-tagged Zfp521 fragments with complemen-
tary disabled ZFs (marked in gray in the schematic drawings) 
and Flag-Runx2 were overexpressed in HEK-293 cells. Cell   
lysates were blotted for HA (second panels) or Flag (third panels).   
Binding of the mutated fragments to Runx2 is indicated. (G) ZFs   
6 and 26 were disabled in full-length Zfp521 (mu_Zfp521).   
Neither Wt Zfp521 nor mu_Zfp521 alone affected the 6×OSE2-luc   
activity. In contrast to Wt Zfp521, mu_Zfp521 only partially an-
tagonized Runx2 activity. Actin was used as a loading control 
in A–F. All results are representative of three to five independent 
experiments. Data are mean ± SEM. *, P < 0.05 versus control. 
#, P < 0.05 versus Runx2.JCB • VOLUME 191 • NUMBER 7 • 2010   1276
(Kang et al., 2005). Zfp521 still retained its full repressive ef-
fect on Runx2 activity in these cells (Fig. 4 D), thereby exclud-
ing HDAC5 as a component of the mechanism.
HDAC3, another class I HDAC, also interacts with and 
antagonizes Runx2, leading to an inhibition of early osteoblast 
differentiation (Schroeder et al., 2004), much like the effect of 
Zfp521. We therefore explored the role of HDAC3 in Zfp521’s 
repression of Runx2 by depleting HDAC3 in ROS cells using a 
short hairpin RNA (shRNA; Fig. S3 B) and found that depleting 
HDAC3 largely prevented the repression of Runx2-induced re-
porter activity by Zfp521 (Fig. 4 E), indicating that HDAC3 in-
deed plays a role in the repression of Runx2 activity by Zfp521. 
Consistent with Zfp521 recruiting HDAC3 to a transcriptional 
repressor complex with Runx2, Zfp521 coimmunoprecipitated 
with both endogenous and overexpressed HDAC3 (Fig. 4 F and 
Fig. S3 C). Most importantly, overexpressing Zfp521 in osteo-
blasts enhanced the association of HDAC3 and Runx2 (Fig. 4 G), 
whereas genetic ablation of Zfp521 reduced it to a great extent 
(Fig. 4 H). Thus, Zfp521 appears to act as a functionally impor-
tant adaptor protein, interacting with both Runx2 and HDAC3 
and enhancing the association of the two proteins, thereby re-
pressing Runx2 transcriptional activity.
Reversal of the skeletal abnormalities in 
Runx2-overexpressing mice by Zfp521
Although Runx2 is indispensable for the commitment of mes-
enchymal precursor cells to the osteoblast lineage (Ducy et al., 
1997; Komori et al., 1997), a sustained high level of Runx2 appears 
to exert a maturational block on differentiating osteoblasts, 
leading to reduced bone formation and an osteoblast-dependent 
increase in osteoclastogenesis and bone resorption, culminating 
in a low bone mass with long-bone fractures in adult mice (Liu 
et al., 2001; Geoffroy et al., 2002). We therefore used the Runx2-
antagonistic properties of Zfp521 to determine whether repres-
sion of Runx2 would reverse the osteopenia in this model.
The Zfp521
Tg mice were crossed with mice overexpress-
ing Runx2 under the control of the 2.3-kb fragment of the rat 
Collagen I type 1 (Col1) promoter (Runx2
Tg mice; Geoffroy 
et al., 2002) to establish double-transgenic Zfp521
Tg;Runx2
Tg 
mice. The rat Col1-2.3kb promoter is active in cells of the   
osteoblast lineage, foremost at the committed matrix-producing 
differentiation stage (Geoffroy et al., 2002). The concurrent   
activity of the ENO2 promoter driving the overexpression of 
Zfp521 and the Col1-2.3kb promoter controlling the ectopic ex-
pression of Runx2 was confirmed in the long bones of adult 
mice (Fig. S4, A and B).
Histomorphometric analysis revealed that Zfp521
Tg mice 
had a high bone mass phenotype with a significant increase in 
bone volume per tissue volume (BV/TV) and bone formation 
seen in tibiae (Fig. 5 A) and lumbar vertebrae (Fig. S5). In con-
trast, and as previously reported (Geoffroy et al., 2002), histo-
morphometric analysis of proximal tibiae of Runx2
Tg mice 
revealed a strikingly low bone mass phenotype characterized by 
a low BV/TV, a reduced bone formation rate, and increased num-
bers of osteoblasts and osteoclasts in the trabecular bone region 
(Fig. 5 A). The cortical bone in tibiae of Runx2
Tg mice was thin, 
which was at least in part caused by a reduced cortical mineral 
Figure 4.  Zfp521 represses Runx2 activity in an HDAC3-dependent manner.  
(A)  Pull-down  (PD)  of  Flag-Runx2  was  performed  in  the  absence  or   
presence of Flag-Zfp521 using biotinylated oligonucleotides (Oligo; wild 
type [Wt] or mutated [mu]) encoding Runx2 consensus sites (rat [OG2] or 
mouse [OSE2] Osteocalcin promoter). Oligonucleotide-bound Flag-Runx2 
was immunoblotted (IB) using anti-Flag antibody. HEK-293 cell lysates were 
analyzed by immunoblotting for overexpressed Flag-Runx2 and Flag-Zfp521. 
(B) Zfp521 prevented Runx2 from activating the 6×OSE2-luc reporter in 
ROS cells. The HDAC inhibitor trichostatin A (TSA) had little effect on the 
reporter alone or Runx2-induced activity but abolished Zfp521’s repres-
sion of Runx2-induced activity. (C) 13Zfp521 repressed the Runx2-driven 
6×OSE2-luc reporter activity in ROS cells as well as full-length Zfp521. 
(D) Zfp521 fully reversed the Runx2-mediated 6×OSE2-luc reporter gene 
activation in Wt ROS cells (ROS17/2.8) and in ROS cells overexpressing a 
dominant-negative form of HDAC5 (ROS-H14). (E) Depleting endogenous 
HDAC3 using shRNA abolished the repression of Runx2-induced 6×OSE2-
luc reporter gene activity by Zfp521. (F) Anti-HDAC3 coimmunoprecipitates 
(IPs) Zfp521 and HDAC3 from Wt calvarial osteoblast lysate. Nonimmune 
IgG was used as a control. HDAC3 is present in total cell lysate (TCL) as 
determined by immunoblotting. (G) Flag-HDAC3 was immunoprecipitated   
with anti-HDAC3 in ROS cells, and the immune complex was immuno-
blotted for Flag-Runx2 with anti-Flag antibody. (H) Endogenous Runx2 was   
immunoprecipitated from calvarial osteoblasts from Wt mice, or mice germ-
line was deleted of Zfp521 (/), and endogenous HDAC3 and Runx2 were 
detected by immunoblotting. The interaction between Runx2 and HDAC3 
was greatly reduced in osteoblasts lacking Zfp521. Actin was used as load-
ing control in F–H. In B–E, results are shown as mean ± SEM. *, P < 0.05 
versus control. 
#, P < 0.05 versus Runx2. P-values are representative of three 
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a reduced number of Osteocalcin-expressing mature osteoblasts 
(Fig. 6 B) and Dentin matrix protein 1 (Dmp-1)–positive osteo-
cytes (Fig. 6 C) in the Runx2
Tg bones, which was reversed by 
overexpressing Zfp521. To confirm the restored osteoblast dif-
ferentiation, the expression of Dmp-1 was quantified in the corti-
cal bone of the same animals (Fig. 6 D). We therefore concluded 
that a sustained high level of Runx2 expression indeed leads to a 
block of osteoblast maturation. Moreover, overexpressing Zfp521 
removes this block, allowing osteoblasts to complete differentia-
tion and restoring the number of osteocytes in the cortex.
The increased bone resorption in Runx2
Tg mice results from 
an osteoblast-dependent increase in osteoclastogenesis caused by 
an increase in the ratio of the osteoblast-derived and osteoclast-
stimulating receptor activator for nuclear factor B ligand (Rankl) 
and the osteoblast-derived soluble Rankl decoy receptor Osteo-
protegerin (Opg; Geoffroy et al., 2002). We confirmed that the 
Rankl/Opg ratio was doubled in bones derived from Runx2
Tg 
mice and this increase was normalized in the Zfp521
Tg;Runx2
Tg 
mice (Fig. 6 E), consistent with the normalized number of less 
mature osteoblasts (Fig. 5 A and Fig. 6 A), which are the main 
sources of Rankl (Giner et al., 2008).
As a consequence of their strikingly reduced bone mass, 
Runx2
Tg mice ultimately developed fractures in the midshaft re-
gion of the tibia (Fig. 6 F) and, less frequently, of the femur and 
the tail vertebrae (not depicted). The ambulatory activity of the 
mice was not compromised, and fracture healing occurred, as 
demonstrated by a callus formation (Fig. 6 F). To compare the 
severity of the fracture phenotype, we established a fracture rate 
(the mean number of hind-limb fractures per animal) for mice of 
each genotype. Zfp521
Tg;Runx2
Tg mice showed an 80% reduced 
fracture rate compared with Runx2
Tg mice (Fig. 6 F), presumably 
owing to the restoration of both bone mass and cortical porosity. 
In summary, Zfp521 overexpression normalized most of the   
phenotypic alterations observed in Runx2
Tg mice, demonstrating 
that Zfp521 can also antagonize Runx2 activity at later stages of 
osteoblast differentiation.
Discussion
Commitment of mesenchymal precursor cells to the osteoblast 
lineage and subsequent osteogenic development involve a tightly 
regulated differentiation program. After commitment, cells pass 
through early differentiation stages to become bone-forming 
osteoblasts and finally reach a terminally differentiated stage 
(Hartmann, 2009) in which they exit the cell cycle and either 
undergo apoptosis, become a bone-lining cell, or adopt the fate of 
a matrix-entrapped osteocyte (Harada and Rodan, 2003). Normal 
bone homeostasis requires balancing the ongoing commitment of 
sufficient numbers of preosteoblasts with the maintenance of 
self-renewing precursors for future osteogenic differentiation 
(Moore and Lemischka, 2006; Kolf et al., 2007) as well as ap-
propriately regulating the rates of early and late differentiation. 
Any imbalance of this system can positively or negatively affect 
the skeletal phenotype.
At the molecular level, many transcription factors and a 
variety of coregulators control the progression of mesenchymal 
precursor cells toward terminally differentiated osteoblasts with 
apposition rate (Fig. 5 B). In addition, the cortices were highly 
porous (Fig. 5 C), consistent with an increased number of active 
osteoclasts in the cortex (Fig. 5 D). Analysis of Zfp521
Tg;Runx2
Tg 
double-transgenic mice revealed that overexpression of Zfp521 
reversed all aspects of the phenotype of the Runx2
Tg mice (Fig. 5, 
A, C, and D) except for the cortical mineral apposition rate and 
cortical thickness, which remained low (Fig. 5 B).
A key feature of the bone phenotype of Runx2
Tg mice is that 
osteoblast maturation is blocked (Liu et al., 2001; Geoffroy et al., 
2002). Consistent with this, we observed an accumulation of 
rather immature Osteopontin-positive osteoblasts (Fig. 6 A) and 
Figure 5.  Zfp521 reverses the low bone mass in Runx2
Tg mice. Phenotypic 
characterization of 5-wk-old Wt, Zfp521
Tg, Runx2
Tg, and Zfp521
Tg;Runx2
Tg 
female  mice  is  shown.  (A)  Histomorphometric  analysis  of  the  trabecu-
lar bone in proximal tibiae (bone volume/tissue volume [BV/TV], bone 
formation  rate/tissue  volume  [BFR/TV],  mineral  apposition  rate  [MAR], 
trabecular  number  [Tb.N],  trabecular  separation  [Tb.Sp],  number  of   
osteoblasts/bone perimeter [N.Ob/B.Pm], and number of osteoclasts/bone 
perimeter [N.Oc/B.Pm]) demonstrates the normalization of the low bone 
mass of Runx2
Tg mice by Zfp521. (B) Analysis of the cortical thickness 
(Ct.Th) in the tibia midshaft. Cortical mineral apposition rate (Ct.MAR) 
was determined by calcein/democycline double labeling (double arrows). 
Bars, 20 µm. (C) Cortical porosity (Ct. porosity) was quantified using Sirius 
red–stained decalcified paraffin-embedded cortical sections. Bars, 100 µm. 
(D)  Tartrate-resistant  acid  phosphatase  staining  of  decalcified  paraffin- 
embedded cortical sections shows increased numbers of osteoclasts and 
resorption in the cortical bone of Runx2
Tg mice compared with Zfp521
Tg 
and Wt mice, which was normalized by Zfp521. Ct.Ar., cortical area. 
Bars, 100 µm. Data are mean ± SEM. n = 4–6 mice per group. *, P < 
0.05 versus Wt. 
#, P < 0.05 versus Runx2
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finding, together with the complex role of Runx2 during osteo-
blast differentiation, led us to analyze the functional consequences 
of altering the relative levels of Runx2 and Zfp521 on early and 
late stages of bone development and homeostasis, specifically 
examining the effects of altering Zfp521 levels during early de-
velopment on the CCD phenotype of Runx2
+/ mice and at later 
stages on the osteopenic phenotype of the Runx2
Tg mouse.
Our results provide genetic evidence that Zfp521 antago-
nizes the early developmental osteogenic function of Runx2   
in vivo. Eliminating one Zfp521 allele in Runx2
+/ mice partially 
rescued the CCD phenotype, whereas overexpressing Zfp521 in 
the Runx2
+/ mice exacerbated the CCD phenotype, delaying 
osteoblast differentiation and subsequent matrix mineralization. 
We also found that overexpressing Zfp521 antagonized most, 
but not all, of the negative effects of Runx2 during later bone 
growth and homeostasis. The diminished trabecular bone for-
mation and bone mass, as well as the increased osteoclasto-
genesis and porosity seen in the cortex of Runx2
Tg mice, were fully 
reversed in Zfp521
Tg;Runx2
Tg mice, and the fracture rate was 
greatly reduced. However, Zfp521 failed to restore the thin cor-
tical bone found in Runx2
Tg mice, perhaps owing to a mineral 
apposition rate that was less increased in cortical than in trabec-
ular bone. Thus, cortical and trabecular bone appear to be differ-
ently regulated, as has been shown in other instances (Compston, 
2007). Collectively, these data demonstrate that Zfp521 an-
tagonizes  both  Runx2-induced  osteogenic  commitment  of 
mesenchymal  precursors  and  the  Runx2-induced  block  of   
osteoblast maturation.
In vitro, Zfp521 dose-dependently antagonized Runx2 
transcriptional activity and Runx2-mediated early stage osteo-
blast differentiation. Although Runx2 is implicated in cell cycle 
regulation (Galindo et al., 2005), Zfp521 did not appear to mod-
ulate proliferation in osteoblasts. Thus, by limiting the progres-
sion of osteoblast differentiation, Zfp521 maintains the pool of 
mesenchymal precursors and early committed osteoblasts, as 
shown by the increased numbers of colony-forming units in the 
marrow of the Zfp521-overexpressing mice. Together, these find-
ings suggest that the antagonism of Runx2 by Zfp521 reduces 
the commitment and/or early differentiation of osteoprogenitors 
cells  while  promoting  osteoblast  maturation  and  increasing 
bone mass in vivo. They do not, however, exclude the possibil-
ity that Zfp521 may also increase bone mass by affecting other 
factors that regulate bone homeostasis. For instance, Zfp521 
has been reported to repress early B cell factor 1 (Ebf1) activity 
in vitro (Bond et al., 2004), and deletion of Ebf1 leads to an in-
crease in bone formation (Hesslein et al., 2009).
In  vitro  analysis  revealed  that  Zfp521  binds  to  Runx2 
within the QA and Runt domains and identified two Zfp521 ZF 
domains (6 and 26) that are critical for this interaction. Mutat-
ing the Zn
2+-coordinating His residues of these ZFs and thereby 
destabilizing the ZF conformation reduced both the binding of 
Zfp521 to Runx2 and the Zfp521-mediated repression of Runx2 
transcriptional activity, confirming the functional importance of 
the  association  of  Zfp521  and  Runx2. The  residual  binding 
could result from partial stabilization of the ZF domain confor-
mations in the context of full-length Zfp521, from the pres-
ence of other Runx2 binding sites that were not apparent in the 
Runx2  playing  a  central  role  (Lian  et  al.,  2006;  Hartmann, 
2009). A rise in Runx2 transcriptional activity is a prerequisite 
for the transition of a mesenchymal precursor cell to an osteo-
progenitor cell (Ducy et al., 1997). In humans, some Runx2 mu-
tations cause CCD (Mundlos et al., 1997), a syndrome that is 
largely recapitulated in Runx2
+/ mice (Otto et al., 1997). Be-
cause the proper development of intramembranous bone is very 
sensitive to changes in Runx2 activity (Lou et al., 2009), Runx2 
activity must be tightly controlled in both a positive and nega-
tive fashion. On the other hand, overexpressing Runx2 in more 
mature  osteoblasts  inhibits  osteoblast  maturation  and  matrix 
protein production (Liu et al., 2001; Geoffroy et al., 2002), in-
dicating that Runx2 plays different roles depending on the stage 
of osteoblast differentiation.
Zfp521 is a recently identified transcriptional coregulator 
that antagonizes Runx2 transcriptional activity in vitro (Wu et al., 
2009). This interesting and potentially biologically relevant 
Figure 6.  Zfp521 relieves the Runx2-induced block of osteoblast matu-
ration. (A–C) Expression of osteopontin (A), osteocalcin (B), and dentin 
matrix protein 1 (Dmp-1; C) was determined by in situ hybridization of 
decalcified tibiae. In the trabecular bone of Runx2
Tg mice, partially dif-
ferentiated Osteopontin-expressing osteoblasts were increased, and ma-
ture Osteocalcin-expressing osteoblasts were decreased compared with 
Zfp521
Tg and Wt littermates, as were Dmp-1–expressing osteocytes in the 
cortical bone. Overexpressing Zfp521 normalized the number of Osteopontin- 
positive cells and restored the abundance of mature osteoblasts and osteo-
cytes in Zfp521
Tg;Runx2
Tg mice. The number of osteocytes in the cortical bone 
was determined per bone volume (Ocy.N./BV). Bars, 100 µm. (D) Changes in 
the number of osteocytes were confirmed by quantifying Dmp-1 mRNA expres-
sion in the cortical bones of the same animals. (E) The increased Rankl/Opg 
ratio in 5-wk-old female Runx2
Tg mice was normalized in Zfp521
Tg;Runx2
Tg 
animals. (F) Radiograms of the right tibia of 12-wk-old male mice. Runx2
Tg 
mice had a mean of two midshaft fractures in hind-limb long bones (frac-
ture rate). The fracture rate was reduced by 80% in Zfp521
Tg;Runx2
Tg ani-
mals. Bars, 2.5 mm. All data are mean ± SEM. n = 4–6 mice per group.   
*, P < 0.05 versus Wt. 
#, P < 0.05 versus Runx2
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Materials and methods
Plasmids
Flag-Runx2  (MASNSL  isoform),  6×OSE2-luc  (both  provided  by  P.  Ducy,   
Columbia University, New York, NY), Flag-HDAC3, pSHAG-HDAC3 shRNA, 
scrambled control plasmids (all provided by J. Westendorf, Mayo Clinic, 
Rochester, MN), and HA-Zfp521 were described previously (Ducy et al., 
1997; Schroeder et al., 2004; Wu et al., 2009). A cDNA encoding Zfp521 
was generated by PCR and cloned between the Sal1–Not1 sites of the 
pGEX-4T-1 vector (GE Healthcare) to obtain GST-Zfp521. The vector encod-
ing  Flag-Zfp521  or  Flag-13Zfp521  was  constructed  by  amplifying  Wt 
Zfp521 or Zfp521 lacking the N-terminal 13 amino acids using pairs of an-
nealing oligonucleotides. The products were subcloned into the Sal1–BamH1 
site of the 3×Flag-BICEP-CMV-2 vector (Sigma-Aldrich). HA-Zfp52113 was 
generated by subcloning the PCR product into the Sal1–BamH1 site of the 
pCMV5-HA vector (Sigma-Aldrich). HA-tagged constructs encoding several 
ZF domains (ZF 1–5, ZF 6–10, ZF 9–15, ZF 9–20, ZF 21–25, and ZF 26–
30) were amplified by PCR, and the products were cloned between the 
Sal1–Not1 sites of the pCMV-HA vector (Takara Bio Inc.). Zinc-coordinating 
His residues of up to five ZFs of the ZF 6–10 and ZF 26–30 fragments were 
simultaneously randomly mutated to Glu using the multisite-directed mutagen-
esis kit (QuickChange; Agilent Technologies) according to the manufacturer’s 
instructions, producing constructs with one or both histidines converted to 
glutamate in one to five of the ZFs. ZF 6 and ZF 26 residues H
264, H
269, 
H
1156, and H
1161 were mutated to E in full-length Zfp521 by site-directed muta-
genesis. Several fragments of Runx2 encoding individual domains or small 
groups of domains were amplified from the pCMV-Flag-Runx2 construct by 
PCR and subcloned in the pcDNA3.1 vector (Invitrogen). All PCR-generated 
constructs were confirmed by sequencing.
Cell cultures
ROS17/2.8 cells, ROS-H14 (both provided by R. Derynck, University of 
California, San Francisco, San Francisco, CA), primary calvarial osteo-
blasts, MC3T3-E1 cells, and HEK-293 cells were cultured in -MEM with 
10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin (all obtained 
from Invitrogen). To induce osteogenic differentiation of primary calvarial 
osteoblasts, culture medium was supplemented with 50 µM ascorbic acid 
and 5 mM -glycerolphosphate (Sigma-Aldrich).
Gene transfections
FuGENE 6 transfection reagent (Roche) was used for transient transfections 
using  a  3:2  FuGENE  6/DNA  ratio  according  to  the  manufacturer’s 
recommendations.
Virus production and infection experiments
Construction of Runx2 and lacZ adenoviruses was previously described 
(Wu et al., 2009). To generate adenovirus encoding Zfp521, Zfp521 was 
fragments, and/or from the stabilization of the Zfp521–Runx2 
interaction by other factors that function as adaptor molecules 
in a larger complex.
Several HDACs have been reported to reduce Runx2 tran-
scriptional activity (Westendorf et al., 2002; Schroeder et al., 
2004; Kang et al., 2005; Jensen et al., 2008, 2009). Although 
Zfp521 attenuates Runx2 activity via HDAC4 in chondrocytes 
(Correa et al., 2010), this study indicates that, in osteoblasts, 
Zfp521 antagonizes Runx2 activity at least in part by recruiting 
HDAC3 to the Runx2 transcriptional complex. Inhibition of class 
I and class II HDACs prevented the Zfp521-induced blockade of 
Runx2 transcriptional activity, as did the depletion of HDAC3 
specifically. In contrast to the requirement for HDAC3, Zfp521’s 
negative effect on Runx2 appears to be independent of HDAC5, 
which also represses Runx2 (Kang et al., 2005) and the HDAC1- 
and HDAC2-containing NuRD complex, which binds to a motif 
at the N terminus of Zfp521 (Bond et al., 2008). The interaction 
between Runx2 and HDAC3 was strikingly enhanced by Zfp521. 
In addition, genetic ablation of Zfp521 strongly reduced the asso-
ciation of Runx2 and HDAC3. Our conclusion that Zfp521 pro-
motes the association of HDAC3 and Runx2 is further supported 
by the location of the Zfp521 binding site within the QA and Runt 
domains of Runx2 because these domains have been reported to 
harbor a TSA-sensitive autonomous repression domain and func-
tion as a binding site for HDAC3 (Schroeder et al., 2004). The 
concept of HDAC3 playing a positive role in bone mass accrual 
despite its negative effect on Runx2 activity is further demon-
strated by a recent study describing the osteoblast-targeted dele-
tion of HDAC3, causing an impaired intramembranous and 
endochondral bone formation (Razidlo et al., 2010).
Interestingly, Runx2 is not the only regulatory protein to 
exert apparently opposite stage-specific effects during osteoblast 
differentiation. Like Runx2, the transcription factor Snail1 is nec-
essary for the early steps of osteoblast development, but its sus-
tained activity in transgenic mice impairs osteoblast differentiation 
(de Frutos et al., 2009). Similarly, high canonical Wnt-signaling 
activity impairs late-stage osteoblast differentiation and/or   
function (Li et al., 2005; van der Horst et al., 2005; Rodda and   
McMahon, 2006), notwithstanding the fact that the canonical 
Wnt pathway facilitates the commitment of mesenchymal pre-
cursor cells to the osteoblast lineage and supports the function of 
early stage osteoblasts. In addition, TGF- signaling is important 
in the maintenance and expansion of the mesenchymal progenitor 
cells but inhibits differentiation along the osteoblast lineage 
(Derynck and Akhurst, 2007). Together with these studies, our 
data reinforce the emerging concept that factors that favor the   
entry and progression of precursors to the osteoblast lineage might 
need to be repressed at later stages of differentiation to allow the 
final steps of osteoblast differentiation and matrix production. 
Zfp521 appears to play an important role in these later events.
In conclusion, we propose a model in which Zfp521 antag-
onizes Runx2 activity at both early and late stages of osteoblast 
differentiation (Fig. 7), thereby both maintaining the number 
of mesenchymal precursor cells and promoting final osteoblast 
maturation, respectively. The repression that Zfp521 exerts on 
Runx2 may therefore contribute to the physiological regulation 
of skeletal development and adult bone mass in mice.
Figure 7.  Model of the regulation of osteoblast differentiation by Zfp521. 
Zfp521 interacts with HDAC3 and Runx2, stabilizing the association of 
these two factors. This corepressor complex represses target gene tran-
scription. Runx2 is required for entry of progenitor cells to the osteoblast 
lineage. Zfp521 antagonizes this early positive effect of Runx2, leading to 
decreased osteoblast differentiation and an increased number of progeni-
tors. Committed osteoblasts express Rankl and stimulate osteoclastogen-
esis. Runx2 antagonizes later stages of osteoblast differentiation, blocking 
osteoblast maturation. This block leads to an increase of Rankl-expressing 
immature osteoblasts and therefore to an increase in bone resorption, a de-
crease in the abundance of terminally differentiated osteoblasts and osteo-
cytes, and ultimately fractures in Runx2
Tg mice. Zfp521 also antagonizes 
this later negative effect of Runx2, thereby removing the maturational block 
and rescuing the low bone mass of Runx2
Tg mice. The high bone mass 
phenotype of Zfp521
Tg mice suggests that Zfp521 exerts a greater effect 
on Runx2 activity at the later stage of osteoblast differentiation.JCB • VOLUME 191 • NUMBER 7 • 2010   1280
contain a Wt (wt, underlined) or mutated (mu, lowercase) Runx2 consensus 
site of the rat Osteocalcin (OG2) promoter: OG2_wt_sense, 5-biotin-CAA-
TCACCAACCACAGCATCCTTTGG-3, and OG2_wt_antisense, 5-CCAA-
AGGATGCTGTGGTTGGTGATTG-3; OG2_mu_sense, 5-biotin-CAATC-
ACCAgtaACAGCATCCTTTGG-3, and OG2_mu_antisense, 5-CCAAAG-
GATGCTGTtacTGGTGATTG-3. In addition, oligonucleotides containing a 
Wt or mutated Runx2 consensus site of the mouse Osteocalcin (OSE2) pro-
moter were used (Ducy and Karsenty, 1995): OSE2_wt_sense, 5-biotin-
GATCCGCTGCAATCACCAACCACAGCA-3, and OSE2_wt_antisense,   
5-GATCTGCTGTGGTTGGTGATTGCAGCG-3; OSE2_mu_sense, 5-biotin-
GATCCGCTGCAATCACCAAgaACAGCA-3, and OSE2_mu_antisense,   
5-GATCTGCTGTtcTTGGTGATTGCAGCG-3.  Flag-Runx2  was  overex-
pressed in HEK-293 cells alone or together with Flag-Zfp521. Cell lysates 
were incubated with polydeoxyinosinic-deoxycytidylic acid (Roche) and 
precleared with streptavidin-agarose (Invitrogen). Pretreated cell lysates 
were incubated with each oligonucleotide pair and streptavidin-agarose.   
The protein–DNA–streptavidin–agarose complex was separated using an 
SDS-PAGE. Flag-Runx2 was detected on immunoblots using an anti-Flag 
antibody (M2).
Quantitative RT-PCR analysis
The mid-diaphysis of the femora was ground in liquid nitrogen followed by 
an RNA extraction using TRIZOL reagent (Invitrogen) and an RNA cleanup 
using the RNeasy Mini kit (QIAGEN) according to the manufacturer’s pro-
tocols. RNA from cells was isolated using the RNeasy Mini kit, including an 
on-column RNase-free DNase 1 digestion according to the manufacturer’s 
instructions. RNA was quantified spectrophotometrically. cDNA was syn-
thesized by reverse transcription. 1 µg of total RNA was mixed with 3 µl of 
an oligonucleotide combination of 0.25 µg/µl oligo-dT12–18 and 0.25 µg/µl 
of random primers (both obtained from Invitrogen) in a 3:1 ratio. The   
volume was adjusted to 20 µl with water, and the mixture was incubated 
for 10 min at 70°C. Reverse transcription was performed in 40 µl of total 
volume after addition of 17 µl of reaction mix containing 8 µl of 5× first   
strand buffer, 4 µl of 5-mmol/µl deoxynucleoside triphosphate, 4 µl of 0.1-M   
DTT, and 1 µl of 200-U/µl SuperScript 2 (all purchased from Invitrogen). 
Incubation was performed at 42°C for 50 min followed by an incubation 
at 70°C for 10 min. Volumes were adjusted to 100 µl by adding 60 µl of 
water. 1 µl cDNA was mixed with 12.5 µl of green supermix (iQ SYBR; 
Bio-Rad Laboratories), 10.5 µl of water, and 0.5 µl of 10-µM sense and 
antisense oligonucleotides. The following oligonucleotides were used for 
gene expression analyses: glyceraldehyde 3-phosphate dehydrogenase, 
5-GGTCGGTGTGAACGGATTTGGC-3  and  5-GCAGTGATGGCATG-
GACTGTGG-3;  Runx2,  5-TCCACAAGGACAGAGTCAGATTACAG-3 
and  5-CAGAAGTCAGAGGTGGCAGTGTCATC-3;  Osx,  5-TCTGCTT-
GAGGAAGAAGCTCACTATGGC-3 and 5-AGGCAGTCAGACGAGCT-
GTGC-3; Dmp-1, 5-CCAGAGGGACAGGCAAATAG-3 and 5-CTGG-
ACTGTGTGGTGTCTGC-3;  Zfp521,  5-CAACGAGTGGGACATCCAG-
GTTC-3 and 5-CATCGTATGATTCTGTAGCTCTGTTTGG-3; Rankl, 5-CAAG-
CTCCGAGCTGGTGAAG-3  and  5-CCTGAACTTTGAAAGCCCCA-3; 
and  Opg,  5-AAGAGCAAACCTTCCAGCTGC-3  and  5-CACGCTGC-
TTTCACAGAGGTC-3. The reactions were performed in a 96-well plate 
using an iCycler (Bio-Rad Laboratories). Samples were denatured at 95°C 
for 3 min. cDNA was amplified by 40 cycles at 95, 57, and 72°C for   
30 s each. All samples were normalized to glyceraldehyde 3-phosphate 
dehydrogenase,  and  relative  expression  of  Zfp521  was  determined   
using the 2
CT method. Data are presented as fold change relative to 
control samples.
Luciferase reporter gene assay
Cells were plated at a density of 2 × 10
5 cells per well in 6-well tissue cul-
ture plates and grown in -MEM until 70–80% confluency. Cells were 
transfected with the 6×OSE2-luc reporter plasmid together with the follow-
ing plasmids as indicated: 1 µg Flag-Runx2, 2 µg HA-Zfp521, 2 µg HA-
mu_Zfp521, 1 µg Flag-HDAC3, and 1 µg each pSHAG-HDAC3 shRNA 
and scrambled control. 17 ng pCMV-Renilla-luciferase (Promega) was used 
for normalization. In all transfection assays, empty vector DNA was used 
to equalize the total amount of DNA. After 24 h, 100 nM TSA (Sigma- 
Aldrich) was added. Luciferase activity was determined 48 h after transfec-
tion using the dual-luciferase reporter assay kit (Promega) as described by 
the manufacturer.
Osteoblast differentiation assay
Cells were washed twice with PBS and fixed for 10 min in 3.7% formalde-
hyde. To stain for ALP activity, cells were incubated with staining mix (35 mg 
Fast blue RR Salt [Sigma-Aldrich] dissolved in 2 ml naphthol AS-BI alkaline 
solution [Sigma-Aldrich] in 48 ml of deionized water) for 30 min in the 
amplified from the pCMV-HA-Zfp521 construct by PCR. The PCR product 
was cloned between the HindIII–EcoRV sites of the pShuttle-CMV vector 
(Qbiogene), and virus production was performed as previously described 
(Wu et al., 2009). MC3T3-E1 cells and primary calvarial osteoblasts from 
Wt mice were seeded at a density of 5 × 10
4 cells per well in 6-well tissue 
culture plates. At 80% confluence, cells were infected with adenoviruses 
encoding Zfp521 and Runx2 as indicated. Virus encoding lacZ was used 
to equalize the amount of infectious particles.
Immunoprecipitation
HEK-293 cells were plated at a density of 8 × 10
5 cells per 10-cm tissue 
culture dish and grown to 70–80% confluence. 2 µg HA-Zfp521 or 2 µg 
of  any  HA-Zfp521–derived  mutant,  1  µg  Flag-Runx2,  and  1  µg  Flag-
HDAC3 were transfected into HEK-293 cells. After 48 h, cells were lysed 
in modified radioimmunoprecipitation assay (mRIPA) buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% IGEPAL CA-630 [Sigma-Aldrich], 0.25% 
deoxycholic acid, 1 mM NaF, 1 mM Na3VO4, 10 µg/ml leupeptin, 10 µg/ml 
aprotinin, 10 µg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride). 
Protein concentrations were determined using the bicinchoninic acid pro-
tein assay kit (Thermo Fisher Scientific). 500 µg of lysate protein was incu-
bated in 1 ml of total volume mRIPA buffer with 2 µg of mouse monoclonal 
anti-HA, 2 µg of rabbit polyclonal anti-HDAC3, 2 µg of rabbit polyclonal 
anti-Runx2, (all obtained from Santa Cruz Biotechnology, Inc.), or 2 µg 
of  anti–mouse  IgG  antibody  (Promega)  at  4°C.  30  µl  of  50%  protein   
A/G–agarose bead slurry (Santa Cruz Biotechnology, Inc.) was added to 
the lysates and incubated for 2–4 h at 4°C. Beads were washed six to 
seven times in 1 ml mRIPA. The immune complexes and 30-µg aliquots of 
total cell lysate of each sample were boiled in 2× SDS-PAGE sample buffer 
and subjected to immunoblot analysis.
Immunoblot analysis
Samples were resolved by SDS-PAGE and transferred to nitrocellulose mem-
branes (GE Healthcare). Membranes were incubated in TBST buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) with the following pri-
mary antibodies: mouse monoclonal anti-Flag antibody (M2; Sigma-Aldrich) 
1:5,000 diluted, mouse monoclonal anti-HDAC2 antibody (Sigma-Aldrich) 
1:1,000 diluted, mouse monoclonal anti-HA antibody, rabbit polyclonal anti-
MTA2 antibody, rabbit polyclonal anti-HDAC3 antibody (all obtained from 
Santa Cruz Biotechnology, Inc.) 1:500 diluted, mouse monoclonal anti-Xpress 
antibody (Invitrogen) 1:1,000 diluted, rabbit polyclonal anti-Zfp521 antibody 
(Wu et al., 2009) 1:500 diluted, or mouse monoclonal antiactin antibody 
(Millipore) 1:10,000 diluted. Membranes were washed in TBST and incu-
bated with either anti–rabbit or anti–mouse IgG horseradish peroxidase– 
conjugated secondary antibody (Promega) 1:10,000 diluted for 1 h in TBST. 
Membranes were washed, incubated for 5 min with the enhanced chemilumi-
nescence system (GE Healthcare), and exposed to film (Kodak).
Zinc removal
Samples were treated as described for immunoprecipitation with the following 
modification: total cell lysates were incubated in 1 ml mRIPA buffer supple-
mented with either 50 mM EDTA or 50 mM 1,10-phenanthroline (both pur-
chased from Sigma-Aldrich) with gentle rotation for 2 h at 4°C to chelate the 
ZF-coordinated zinc ions. Lysates were precleared two times with 30 µl of a 
50% slurry of protein A/G–agarose beads followed by immunoprecipitation.
GST pull-down
GST-Zfp521 and GST alone were expressed in DH5- competent Esche-
richia coli (Invitrogen). Bacterial cultures were incubated with 0.5 mM IPTG 
(American Bioanalytical) for 3 h to induce recombinant protein expression. 
Bacteria were lysed in 10 ml of bacterial protein extraction reagent (B-PER; 
Thermo Fisher Scientific) containing 1 mM NaF, 1 mM Na3VO4, 10 µg/ml 
leupeptin, 10 µg/ml aprotinin, 10 µg/ml pepstatin, and 1 mM phenyl-
methylsulfonyl fluoride. Lysates were sonicated on ice and cleared by cen-
trifugation. GST alone or GST-Zfp521 was purified by incubating the 
supernatants with glutathione–Sepharose beads (GE Healthcare) overnight 
with gentle rotation at 4°C. HEK-293 cells were transfected with 5 µg of 
plasmid  DNA  encoding  Xpress-tagged  Wt  Runx2  and  Xpress-tagged 
Runx2 mutants. Transfected cells were lysed, and 500 µg of total cell lysate 
protein was incubated overnight with 50 µl of a 50% slurry of bead-bound 
GST or GST-Zfp521 in a total volume of 1 ml mRIPA with gentle agitation 
at 4°C. Beads were washed four times with mRIPA buffer, boiled in 2× 
SDS-PAGE sample buffer, and subjected to immunoblot analysis.
DNA affinity precipitation assay
All  sense  oligonucleotides  were  biotinylated  at  the  5  nucleotide  and   
annealed to their complementary strand. The following oligonucleotides 1281 Zfp521 controls bone mass • Hesse et al.
Skeletal analyses
Offspring of the Zfp521
Tg × Runx2
Tg cross were injected 7 and 2 d before 
sacrifice  with  calcein  (40  mg/kg  of  body  weight)  and  democycline   
(20 mg/kg of body weight; both obtained from Sigma-Aldrich), respectively. 
Tibiae of 5-wk-old female mice were collected and fixed in 3.7% PBS-
buffered  formaldehyde.  For  histomorphometrical  analysis,  tibiae  were 
embedded  in  methylmethacrylate,  and  Toluidine  blue  and  von  Kossa 
stainings were performed using 5-µm sagittal sections. Quantitative bone 
histomorphotric measurements were performed according to standard-
ized protocols (Parfitt et al., 1987) using the OsteoMeasure system (Osteo-
Metrics). Cortical porosity was determined after staining with Sirius red. 
Tartrate-resistant acid phosphatase staining was performed after decalci-
fication and paraffin embedding. All histological images were obtained 
at room temperature using a microscope (Eclipse E800; Nikon) with a 
20× (no medium; NA 0.50) objective fitted with a camera (DP71) and 
software (DP controller; Olympus). Plain radiographs were taken (29 kV 
for 10 s) using an x-ray apparatus (Micro 50; Micro Focus Imaging). 
Films were scanned (Scanjet 5530) and saved (Photosmart Studio soft-
ware). For whole-mount skeletal preparations, skins were removed, and 
mice were eviscerated. Samples were stained with Alcian blue/Alizarin 
red  solution  (644  ml  of  95%  ethanol/liter,  131  ml  acetic  acid/liter,   
47 mg Alcian blue/liter, and 20 mg Alizarin red/liter) for 5 d followed 
by digestion using 1.8% KOH until the soft tissue was cleared. Samples 
were preserved in 50% glycerol. Skeletal elements remained in glycerol, 
and images were taken at room temperature using a microscope (Stereo 
Discovery V8; Carl Zeiss, Inc.) with a Plan S 1.25–1.6× FWD 81-mm ob-
jective equipped with a camera (Axiocam HRC REV.2; Carl Zeiss, Inc.) 
and basic software (AV4; Carl Zeiss, Inc.). The length of the mineralized 
clavicle and the hyoid bone was measured by drawing a scale bar along 
the mineralized tissue using the microscope image software. To quantify 
the fontanelle area, three coronal diameters (rostral, central, and caudal) 
were measured, and the mean coronal diameter was determined. The 
mean of the coronal diameter and the sagittal diameter were then used 
to calculate the approximate fontanelle area.
In situ hybridization
[
35S]UTP-labeled riboprobes to detect transcripts encoding Osteocalcin, 
Osteopontin, and Dmp-1 (all provided by B. Lanske, Harvard School of 
Dental Medicine, Boston, MA) were synthesized from linearized plasmids 
using an in vitro transcription kit (Promega) and [
35S]UTP (GE Healthcare). 
In situ hybridization was performed on decalcified and paraffin-embedded 
proximal tibiae. After removing paraffin by xylene, samples were rehy-
drated using an ethanol series. Sections were treated with proteinase K 
and 4% paraformaldehyde followed by incubation with 0.2 N HCl. 0.25% 
acetic anhydride in triethanolamine buffer was used for acetylation. Before 
hybridization, sections were dehydrated in ethanol and air dried. Sections 
were then hybridized with 
35S-labeled sense riboprobes in a humidified 
chamber at 50°C for 16 h. Sections were washed with 2× SSC and 2× 
SSC/50% formamide at 50°C and treated with RNase at 37°C for 20 min. 
After dehydration sections were air dried and coated with emulsion (NTB2, 
1:1  dilution  with  water;  Kodak),  they  were  developed  with  developer 
(Dektol) and fixed with fixer (Kodak). Before analysis, sections were counter-
stained with hematoxylin and eosin. Osteocytes were counted per bone 
volume in the cortex of the mid-diaphysis. Images were taken at room tem-
perature using a microscope (Eclipse E800) with a 20× (no medium; NA 
0.50) objective and a camera (DP71) with DP controller software.
Microcomputed tomography
3D vertebral body trabecular bone properties were analyzed. The fifth 
lumbar vertebral bodies (L5) of four Wt mice and nine Zfp521
Tg mice were 
analyzed using high-resolution microcomputed tomography with a fixed 
isotropic voxel size of 10.5 µm (70 peak kV at 114 A; Viva40 micro-CT; 
Scanco Medical AG). The cortical bone was manually excluded from the 
analysis. A fixed global threshold of 190 mg HA/cm
3 was selected, which 
allowed the rendering of mineralized tissue only. This threshold was veri-
fied by manually evaluating 10 single tomographic slices from four sam-
ples  per  group  to  isolate  the  mineralized  tissue  and  to  preserve  its 
morphology  while  excluding  nonmineralized  tissues.  All  analyses  were 
performed on the digitally extracted bone tissue using 3D distance tech-
niques (Scanco Medical AG).
Statistics
Mean values and the SEM were calculated. To determine significant differ-
ences, the means of all groups were first analyzed by analysis of variance. 
If an F test yielded significant results (P < 0.05), groups were compared   
dark. Images of stained cells were obtained using a scanner (Scanjet 
5530) and imaging software (Photosmart Studio; Hewlett-Packard). ALP 
activity in total cell lysate was quantified using an ALP kit (LabAssay; Wako 
Chemicals USA, Inc.) according to the manufacturer’s instructions.
Animals
The ENO2-tTA mice (Chen et al., 1998), TetOp-Zfp521 mice (Wu et al., 
2009), Runx2
+/ mice (provided by B. Olsen, Harvard School of Dental 
Medicine, Boston, MA; Otto et al., 1997), and Col1-2.3kb–Runx2 mice 
(referred to as Runx2
Tg mice) were described previously (Geoffroy et al., 
2002). Zfp521
+/ mice were generated using standard recombineering 
techniques and provided by S. Warming (Genentech, South San Fran-
cisco, CA). Animals were genotyped by standard PCR (95°C for 15 s, 
60°C for 30 s, and 72°C for 30 s for 35 cycles) using the following   
oligonucleotides: Zfp521_Wt_sense, 5-GCTCCTTCACATGCTCACA-3; 
Zfp521_Wt_antisense, 5-CTGGCATGGGTAAGGCAGT-3; and Zfp521_Ko_
antisense,  5-CTCCGAGAGTTTGAGTGCAA-3.  The  following  fragments 
were obtained: 502-bp 
+/+ band (Wt sense + Wt antisense), 382-bp
/ 
band (Wt sense + Ko antisense), and 502-bp + 382-bp
+/ band (Wt  
sense + Wt antisense + Ko antisense). Zfp521
+/ mice were mated   
with Runx2
+/ mice to obtain Zfp521
+/+;Runx2
+/+, Zfp521
+/;Runx2
+/+, 
Zfp521
+/+;Runx2
+/,  and  Zfp521
+/;Runx2
+/  mice.  Runx2
+/  and 
Runx2
Tg mice were mated with TetOp-Zfp521 mice. F1 mice with the geno-
type  Runx2
+/;TetOp-Zfp521  or  Runx2-TG;TetOp-Zfp521  were  crossed 
with mice homozygous for ENO2-tTA. All offsprings of the F2 generation 
carried one ENO2-tTA transgene and had one of the following genotypes: 
Runx2
+/+;TetOp-Zfp521-Wt,  Runx2
+/+;TetOp-Zfp521
Tg,  Runx2
+/;TetOp-
Zfp521-Wt,  Runx2
+/;TetOp-Zfp521
Tg,  Runx2-Wt;Zfp521-Wt,  Runx2-
Wt;Zfp521
Tg,  Runx2
Tg;Zfp521-Wt,  or  Runx2
Tg;Zfp521
Tg.  These  mating 
strategies provided all experimental mice as well as all controls. Mice from 
all crosses appeared at the expected Mendelian ratio. Littermates were 
used for analysis.
Isolation of primary osteoblasts
Calvariae were dissected from 1–3-d-old neonatal mice and sequentially 
digested for 15 min in -MEM containing 0.1% collagenase and 0.2% dis-
pase (both purchased from Roche). Cells obtained from fractions 2–3 were 
combined according to the genotype and expanded in -MEM containing 
10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Colony-forming unit assays
Colony-forming unit assays (CFU-F and CFU-OB) were performed using 
bone marrow cells from Zfp521
Tg mice and control littermates. Cells were 
obtained by flushing the marrow cavity of the femur with -MEM contain-
ing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin using a 
23-gauge  needle.  Cells  were  homogenized  by  gentle  pipetting  and 
counted using a hemocytometer. Nucleated cells were seeded at a density 
of 1.5 × 10
6 cells per well in a 6-well dish and maintained under osteo-
genic culture conditions. To determine CFU-F, cells were stained for ALP   
after 10 d in culture. Cell colonies containing at least 20 cells were desig-
nated CFU-F. For the determination of CFU-OB, cells were maintained for 20 
d and then stained for mineralization using the von Kossa stain. Mineralized 
nodules were designated CFU-OB.
Proliferation assay
Calvarial  osteoblasts  from  Zfp521
Tg  mice  and  Wt  littermates  were 
plated in triplicate at a density of 10
5 cells per well in a 6-well plate. 
On the next day, cells were incubated with 1 µCi [
3H]thymidine per well 
for 4 h at 37°C. Cells were dissolved in 1% SDS, and [
3H]thymidine in-
corporation  was  determined  using  a  scintillation  counter  (LS  6500; 
Beckmann Coulter).
Immunocytochemistry
Calvarial osteoblasts from Zfp521
Tg mice and Wt littermates were cultured 
on glass coverslips in osteogenic medium for 5 d. Cells were fixed in 3.7% 
formaldehyde and immunostained with rabbit polyclonal anti-Runx2 anti-
body at a 1:100 dilution and Alexa Fluor fluorescent conjugated second-
ary antibody (Invitrogen). ToPro (Invitrogen) was used at a 1:1,000 dilution 
for nuclear labeling. Slides were mounted using FluorSave (EMD). Images 
were obtained at room temperature using a laser-scanning microscope 
(LSM 510 Meta; Carl Zeiss, Inc.) equipped with a Plan Neofluar 63×/1.4 
NA water immersion lens and LSM 510 software. To prevent interference 
between fluorochromes, each channel was imaged sequentially using the 
multitrack recording module before merging. Total enhancements were per-
formed using Photoshop (CS2; Adobe).JCB • VOLUME 191 • NUMBER 7 • 2010   1282
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the  Zfp521-mediated  repression  of  the  Runx2-induced  early  osteoblast 
differentiation. Fig. S2 demonstrates the interaction between HA-Zfp521 
and  Flag-Runx2  and  the  reduced  interaction  of  HA-tagged  mutated 
Zfp521  with  Flag-Runx2.  Fig.  S3  displays  the  disabled  interaction  of 
HA-13Zfp521 with components of the NuRD complex, the efficiency of 
shHDAC3, and the interaction of HA-Zfp521 with Flag-HDAC3. Fig. S4   
shows the concurrent expression of the Zfp521 and the Runx2 transgenes   
in the long bones of adult Zfp521
Tg and Runx2
Tg mice, respectively. Fig. S5   
demonstrates the high bone mass in the lumbar spine of Zfp521
Tg mice. 
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